| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_219f863c3f9ccb2e751965f194956649
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ab2ccd1ab7267e89db3f59691ca8118d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-108
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-20 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-765 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-00 |
| filingDate |
2014-02-14^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08c9e53f1c8843f23ca8f3c63be6b2b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2217f1586d5339bb85fdfdc7012bed5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1341a697975fd9d103d9e813ebc318db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad2e722371a8ce5513c44f2627ab6896 |
| publicationDate |
2014-08-21^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2014125082-A1 |
| titleOfInvention |
Pharmacokinetic animal model |
| abstract |
The present invention relates to a method of assessing pharmacokinetic properties of a variant of human serum albumin using a non-primate animal species where the native albumin of the animal provides minimal competition for HSA binding to the FcRn receptor in said animal. In the non-primate animal species,the binding affinity of wild type HSA to the native FcRn of said animal is the same as or higher than the binding affinity of the native albumin of said animal to the native FcRn. The present invention also relate to animal models which are particularly suitable for assessing pharmacokinetics of human serum albumin variants. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020092202-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021044362-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018096396-A1 |
| priorityDate |
2013-02-16^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |